

## MID-CYCLE COMMUNICATION

**Application type and number:** Original BLA STN 125591/0  
**Product name:**  
**Applicant:** CSL Behring Recombinant Facility AG  
**Action Due Date:**  
**Meeting date & time:** November 19, 2015, 9:30 am – 10 am EST  
**Telecon Numbers** (b) (4) Conference ID: (b) (4)  
**Committee Chair:** Alexey Khrenov, PhD  
**RPM:** Thomas J. Maruna

**Purpose:** To provide an update on the review status of the BLA

### FDA Attendees:

Thomas, Senior Regulatory Management Officer, CBER/OBRR  
Alexey Khrenov, PhD, CMC Reviewer, CBER/OBRR/DHRR/LH

### CSL Behring Attendees

Alex Veldman, MD, Global Clinical Program Director, Clinical R&D  
Angela Azzara, Global Regulatory Affairs Regional Manager, North America  
Anthony Stowers, PhD, Senior Vice President, Recombinant Factor Development  
Christine Joch, Clinical R&D  
Debra Bensen-Kennedy, MD, Global Therapeutic Area Head, Clinical R&D  
Dirk Bruns-Nagel, Senior Manager, Analytical Services Quality Coordinator Recombinant  
Hubert Metzner, Director, Process Development  
John Roberts, Director, Clinical Pharmacology, Clinical R&D  
Katie St. Ledger, Principal Scientist, Clinical R&D  
Kevin Darryl White, MBA, RAC, Senior Director, Global Regulatory Affairs, Head Regional  
North America  
Martina Schneider, Global Regulatory Affairs, Development Products Lead  
Nicole Blackman, Associate Director, Global BioStatistics, Clinical R&D  
Norbert Schulze, Director, CMC Lead  
Reiner Laske, Vice President, Quality Management  
Sabine Pestel, Senior Manager, Pharmacokinetic, Pre-clinical R&D  
Tanja Rosenberg, Director, Clinical Safety Physician  
Thomas Nassauer, Global Regulatory Affairs Established Products and CMC Team Lead

## **Discussion Summary:**

1. No major issues in the BLA have been identified by the review committee to date.
2. The review of the clinical data to date has not raised any major safety or efficacy concerns. The response to the IR regarding HIV-related data discrepancies is still under review.
3. A number of CMC issues with regard to specifications, analytical method validations and post-approval stability commitments were identified. An Information Request is being prepared and will be sent shortly.
4. The method to be used for potency assignment and labeling (one-stage vs. chromogenic) is still under discussion. The decision hasn't been made yet.
5. The change of language for on-demand indication is requested in the labeling. New recommended language is "On demand treatment and control" (not "control and prevention"). The comprehensive discussion of labeling will occur after potency issue is resolved.
6. The current thinking of the review committee is that this BLA will not be presented at Blood Products Advisory Committee meeting. However the external experts will be involved to help resolve the potency issue.
7. The late-cycle meeting will be scheduled for mid-February 2016. The format of the meeting (i.e., a face-to-face meeting or a teleconference) will be determined in the course of the next two months

**END**